Y 20811 | CAS#104363-98-6

MedKoo Cat#: 341071 | Name: Y 20811

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Y 20811 is a biochemical.

Chemical Structure

Y 20811

CAS#104363-98-6

Theoretical Analysis

MedKoo Cat#: 341071

Name: Y 20811

CAS#: 104363-98-6

Chemical Formula: C20H19N2NaO3

Exact Mass: 358.1293

Molecular Weight: 358.37

Elemental Analysis: C, 67.03; H, 5.34; N, 7.82; Na, 6.42; O, 13.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Y 20811; Y-20811; Y 20811

IUPAC/Chemical Name

Benzoic acid, 4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-, monosodium salt

InChi Key

HRUWEADDSLYBSH-FSRHSHDFSA-M

InChi Code

InChI=1S/C20H20N2O3.Na/c1-12-4-5-16(22-7-6-21-11-22)10-17(12)19(23)18-13(2)8-15(20(24)25)9-14(18)3;/h4-11,19,23H,1-3H3,(H,24,25);/q;+1/p-1/t19-;/m1./s1

SMILES Code

[Na+].C(c1cc(c(c(c1)C)[C@@H](c1c(ccc(c1)n1ccnc1)C)O)C)(=O)[O-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 358.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sakai H, Suzuki T, Murota M, Takahashi Y, Takeguchi N. Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2. J Physiol. 2002 Aug 15;543(Pt 1):261-71. PubMed PMID: 12181297; PubMed Central PMCID: PMC2290489. 2: Suzuki T, Sakai H, Takeguchi N. Thromboxane A(2)-mediated Cl(-) secretion induced by platelet-activating factor in isolated rat colon. Eur J Pharmacol. 2000 Jul 21;400(2-3):297-303. PubMed PMID: 10988347. 3: Sakai H, Sato T, Hamada N, Yasue M, Ikari A, Kakinoki B, Takeguchi N. Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon. J Physiol. 1997 Nov 15;505 ( Pt 1):133-44. PubMed PMID: 9409477; PubMed Central PMCID: PMC1160099. 4: Sumiyoshi A, Asada Y, Marutsuka K, Hayashi T, Kisanuki A, Tsuneyoshi A, Sato Y. Platelets and intimal thickening. Ann N Y Acad Sci. 1995 Jan 17;748:74-85; discussion 85. Review. PubMed PMID: 7695225. 5: Matsumoto Y, Noguchi Y, Inui J. [Effect of Y-20811, a thromboxane A2 synthetase inhibitor, on the arachidonic acid-induced response in the blood-superfused canine coronary artery]. Nihon Yakurigaku Zasshi. 1994 Feb;103(2):59-66. Japanese. PubMed PMID: 8112690. 6: Fujimura M, Mikashima H. Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits. Thromb Res. 1993 May 1;70(3):233-44. PubMed PMID: 8327988. 7: Sato N, Endo T, Kiuchi K, Hayakawa H. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs. J Cardiovasc Pharmacol. 1993 Mar;21(3):353-61. PubMed PMID: 7681494. 8: Umemura K, Asai Y, Uematsu T, Nakashima M. Role of thromboxane A2 in a microcirculation disorder of the rat inner ear. Eur Arch Otorhinolaryngol. 1993;250(6):342-4. PubMed PMID: 8260145. 9: Fukuchi M, Uematsu T, Araki S, Nakashima M. Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):550-4. PubMed PMID: 1470226. 10: Fujii T, Matsuzaki M, Oda T, Sakai H, Tanaka N, Yano M, Miura T, Kohno M, Katayama K, Kusukawa R. Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis. Jpn Circ J. 1992 Nov;56(11):1191-7. PubMed PMID: 1453545. 11: Takiguchi Y, Hirata Y, Wada K, Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb Res. 1992 Aug 15;67(4):435-45. PubMed PMID: 1412222. 12: Hayashi T, Asada Y, Kisanuki A, Sumiyoshi A. Effects of antithrombotic drug, Y-20811 on mural thrombus formation and intimal thickening following intimal injury. Thromb Res. 1992 Jul 1;67(1):81-94. PubMed PMID: 1440516. 13: Matsumoto Y, Ochi H, Aihara K, Inui J, Ikegami K. Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs. Eur J Pharmacol. 1992 Mar 24;213(2):167-70. PubMed PMID: 1521557. 14: Mikashima H, Ochi H, Muramoto Y, Hirotsu K, Arima N. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor. Biochem Pharmacol. 1992 Jan 22;43(2):295-9. PubMed PMID: 1739418. 15: Kagoshima M, Tomomatsu N, Fukuda T, Mikashima H, Terasawa M. [Effects of Y-20811, a specific thromboxane A2 synthetase inhibitor, on chemical mediator-induced bronchoconstriction in guinea pigs]. Nihon Yakurigaku Zasshi. 1991 May;97(5):277-86. Japanese. PubMed PMID: 1908816. 16: Kagoshima M, Tomomatsu N, Aratani H, Terasawa M. Effect of Y-20811, a long-lasting thromboxane A2 synthetase inhibitor, on antigen-induced airway hyperresponsiveness in guinea pigs. Int Arch Allergy Appl Immunol. 1991;96(3):238-43. PubMed PMID: 1804796. 17: Iwata T, Mikashima H, Takamatsu R. Correlation between pharmacokinetics and pharmacologic effects of a new imidazole thromboxane synthetase inhibitor. J Pharm Sci. 1990 Apr;79(4):295-300. PubMed PMID: 2352139. 18: Mikashima H, Muramoto Y. Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. Thromb Res. 1990 Feb 15;57(4):499-505. PubMed PMID: 2326771. 19: Iwata T, Mikashima H, Isobe M, Takamatsu R, Yokobe T. [Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. II. Pharmacokinetics of intact drug and main metabolite in dog]. Yakugaku Zasshi. 1989 Nov;109(11):853-7. Japanese. PubMed PMID: 2614667. 20: Iwata T, Tsuruda M, Demizu K, Isobe M, Takamatsu R, Yokobe T. [Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. I. Isolation and structure elucidation of urinary metabolite in dog]. Yakugaku Zasshi. 1989 Sep;109(9):636-41. Japanese. PubMed PMID: 2607414.